Importance of the plasma soluble HLA-G levels for prognostic stratification with traditional prognosticators in colorectal cancer
Metrics: PDF 807 views | HTML 1316 views | ?
Jing-Bo Li1, Yan-Yun Ruan2, Bin Hu1, Shan-Shan Dong2, Tie-Nan Bi3, Aifen Lin2 and Wei-Hua Yan1,4
1Medical Research Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, People’s Republic of China
2Human Tissue Bank, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, People’s Republic of China
3Department of Gastrointestinal Surgery, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, People’s Republic of China
4Department of Laboratory Medicine, Xianju People’s Hospital, Xianju, Zhejiang, People’s Republic of China
Wei-Hua Yan, email: firstname.lastname@example.org
Aifen Lin, email: email@example.com
Keywords: soluble HLA-G, colorectal cancer, prognosis
Received: November 07, 2016 Accepted: March 13, 2017 Published: March 22, 2017
An increased peripheral soluble HLA-G (sHLA-G) expression has been observed in various malignancies while its prognostic significance was rather limited. In this study, the prognostic value of plasma sHLA-G in 178 colorectal cancer (CRC) patients was investigated. sHLA-G levels were analyzed by specific enzyme-linked immunosorbent assay. Data showed sHLA-G levels were significantly increased in CRC patients compared with normal controls (36.8 U/ml vs 25.4 U/ml, p = 0.009). sHLA-G in the died were obviously higher than that of alive CRC patients (46.8 U/ml vs 27.4 U/ml, p = 0.012). Patients with sHLA-G above median levels (≥ 36.8 U/ml, sHLA-Ghigh) had a significantly shorter survival time than those with sHLA-Glow (< 36.8 U/ml, p < 0.001), and sHLA-G could be an independent prognostic factor for CRC patients. With stratification of clinical parameters in survival by sHLA-Glow and sHLA-Ghigh, sHLA-G exhibited a significant predictive value for CRC patients of the female (p = 0.036), the elder (p = 0.009), advanced tumor burden (T3 + 4, p = 0.038), regional lymph node status (N0, p = 0.041), both metastasis status (M0, p = 0.014) and (M1, p=0.018), and clinical stage (I + II, p = 0.018), respectively. Summary, our data demonstrated for the first time that sHLA-G levels is an independent prognosis factor and improves the prognostic stratification offered by traditional prognosticators in CRC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.